Jean Paul Fermand

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma

Michel Attal, Valérie Lauwers‐Cancès, Cyrille Hulin et al. · New England Journal of Medicine · 2017 · 1.2K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

Philippe Moreau, Michel Attal, Cyrille Hulin et al. · The Lancet · 2019 · 953 citations · Full text

Medicine, Hematology, Pharmacotherapy +14

Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients.

Philippe Rousselot, S Labaume, Jean‐Pierre Marolleau et al. · PubMed · 1999 · 227 citations

Medicine, Oncology, Pharmacology +15

Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide–refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02

Xavier Leleu, Michel Attal, Bertrand Arnulf et al. · Blood · 2013 · 208 citations

Medicine, Hematology, Pharmacotherapy +16

Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma

Olivier Hermine, Hervé Dombret, Joël Poupon et al. · The Hematology Journal · 2004 · 125 citations

Medicine, Hematology, Oncology +11